REGITINE Drug Patent Profile
✉ Email this page to a colleague
When do Regitine patents expire, and when can generic versions of Regitine launch?
Regitine is a drug marketed by Novartis and is included in one NDA.
The generic ingredient in REGITINE is phentolamine mesylate. There are four drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the phentolamine mesylate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Regitine
A generic version of REGITINE was approved as phentolamine mesylate by HIKMA on March 11th, 1998.
Summary for REGITINE
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 61 |
Clinical Trials: | 2 |
Patent Applications: | 3,840 |
Formulation / Manufacturing: | see details |
DailyMed Link: | REGITINE at DailyMed |
Recent Clinical Trials for REGITINE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Early Phase 1 |
University of Pennsylvania | Early Phase 1 |
National Institutes of Health (NIH) | Early Phase 1 |
Anatomical Therapeutic Chemical (ATC) Classes for REGITINE
US Patents and Regulatory Information for REGITINE
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Novartis | REGITINE | phentolamine mesylate | INJECTABLE;INJECTION | 008278-003 | Approved Prior to Jan 1, 1982 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |